[Comment] Testing early haemostatic therapy for acute intracerebral haemorrhage

00:00 - 04 Feb 2026

The clinical severity, narrow time window to reduce bleeding, and variable care pathways for patients with spontaneous (non-traumatic) intracerebral haemorrhage (ICH) are enormous challenges to be overcome by treatments for this serious condition. In this issue of The Lancet, Joseph P Broderick and colleagues1 present the results of the FASTEST trial, a monumental effort to establish the safety and efficacy of the potent haemostatic agent, intravenous recombinant factor VIIa, administered to patients within 2 h of the onset of ICH.